Navigation Links
Nuvasive Reports Third Quarter 2008 Financial Results
Date:10/22/2008

2008 2007

Assets

Current assets:

Cash and cash equivalents $104,388 $61,915

Short-term investments 72,157 19,247

Accounts receivable, net 46,072 27,496

Inventory, net 58,418 36,280

Prepaid expenses and other current assets 3,352 1,240

Total current assets 284,387 146,178

Property and equipment, net of

accumulated depreciation 73,159 43,538

Intangible assets, net of accumulated

amortization 57,041 24,496

Long-term marketable securities 45,148 8,536

Other assets 8,892 2,939

Total assets $468,627 $225,687

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued liabilities $20,078 $13,839

Accrued payroll and related expenses 13,853 12,075

Royalties payable 2,310 2,076

Total current liabilities 36,241 27,990

Senior convertible notes 230,000 -

Long-term liabilities 27,226 1,119

Commitments and contingencies

Stockholders' equity:

Common stock 36 35

Additional paid-in capital 374,695 364,469

Accumulated other comprehensive income

(loss) (363) 54

Accumulated deficit (1
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. NuVasive Completes Acquisition of Osteocel Biologics Business
3. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
4. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
9. NuVasive to Host Investor Reception on September 11, 2007
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 College of DuPage students ... gaining invaluable real-world experiences while serving biophysics internships at ... The students will be working as a part ... at IIT. The internship came about from a ... Physics; Dr. Kathy Finan , Biology; and Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... PALO ALTO, Calif. , July 1, 2015 ... company focused on the development of groundbreaking drugs ... sclerosis (ALS), announced today that Robert G. ... Research Center at Sutter Health,s California Pacific Medical ... from The ALS Association for $1.5 million to ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, ... PA. , The presentation took place on Tuesday, June 16 and provided ... development of APX3330 for the treatment of pancreatic cancer. A copy of the ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... Large Well-Known Product and Continues ... of Antibody Therapeutics Pipeline -, BRITISH COLUMBIA, Canada, ... TSX Venture: IXS;, http://www.ixsbio.com ), a drug development company ... Dynamic Cross Linking,(DXL(TM)) technology, announces the development of a ...
... reported results for the quarter ended September 30, 2008.,Revenue ... to $112,000 for,the quarter ended September 30, 2007. Revenue ... compared to $715,000 for the nine months,ended September 30, ... quarter of 2008 were,$17.3 million compared to $19.8 million ...
... Residual Vascular Risk Reduction: The Global Call to Action, ... Initiative:,R3i, KEY FACTS:, Residual Risk Reduction Initiative (R3i) ... unaddressed by current standards of,care in millions of patients with ... Audubon Room, Ritz Carlton Hotel, 921 Canal Street, New Orleans, ...
Cached Biology Technology:InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 2InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 3Dendreon Reports Third Quarter 2008 Financial Results 2Dendreon Reports Third Quarter 2008 Financial Results 3Dendreon Reports Third Quarter 2008 Financial Results 4Dendreon Reports Third Quarter 2008 Financial Results 5
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... German . Much celebration at the ... has approved funding for a long-term research project by Professors ... and Dr. Frank Spinath from Saarland University. They are studying ... 4,000 pairs of twins living in Germany. The name of ...
... to a new study from the Slone Epidemiology Center (SEC) ... age 11 had a greater likelihood of adult-onset asthma compared ... The study, which is published online in ... led by Patricia Coogan, DSc, senior epidemiologist at SEC and ...
... discovered by a Northwestern University professor and now tested ... been shown to alleviate symptoms within hours, have good ... seven days from a single dose. The ... memory -- a very different approach from existing antidepressants. ...
Cached Biology News:German Research Foundation to fund globally unique twin study on social inequality 2Abuse during childhood linked to adult-onset asthma in African-American women 2New antidepressant acts very rapidly and is long lasting 2New antidepressant acts very rapidly and is long lasting 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: